News & media
The Treatment Journey of a Patient with CLL
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with…
What Is the Outlook for Older Patients with CLL?
The prognosis for patients with chronic lymphocytic leukemia (CLL) has seen recent improvements.
John N. Allan, MD, on Research Coming Out of ASH for CLL
The assistant professor of Medicine in the division of Hematology and Medical Oncology at Weill…
An Analysis of CLL in Adolescents and Young Adults
Most patients diagnosed with chronic lymphocytic leukemia (CLL) are older; the median age at…
Case Study: COVID-19 and the Coexistence of CLL
Many symptoms of SARS-CoV-2 (COVID-19) can be concealed due the coexistence of malignant…
Venclexta PBS listed as first line therapy for CLL patients unfit for chemotherapy
VENCLEXTA plus obinutuzumab is a combination, fixed duration therapy for previously untreated…
ASH 2020 CLL Daily Wrap-Up
Join Patient Power on Tuesday, December 8th at 4pm PT/7pm ET for a live recap of the latest chronic…
CLL and COVID-19: What Should Patients Know About Vaccines?
With the flu season approaching and whispers of a vaccine for COVID-19 in the works, CLL patients…
CLL Advocates NZ Newsletter Issue 6
Welcome to issue 6 of the CLL Advocates newsletter. This month's newsletter shares our latest…
NICE recommends new chemo-free chronic lymphocytic leukaemia treatment
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and…
When and How CLL, SLL Should Be Treated
New treatment options are outperforming the “old-fashioned” chemotherapy regimens for patients with…
Dr. Awan on the Importance of Collaborative Care in CLL
Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.
Different Therapies and Modalities for Treatment of CLL in the Second Line
During a Targeted Oncology Case Based Peer Perspectives event, Danielle Brander, MD, assistant…
CLL Advocates NZ Newsletter Issue 5
Welcome to issue 3 of the CLL Advocates newsletter. This month's newsletter focuses on research and…
Novel Prognostic Model Predictive of Survival in Ibrutinib-Treated CLL
While there are existing prognostic indices, none specifically evaluate for criteria known to be…
CLL Advocates NZ Launches a New Zealand Patient Guide
CLL Advocates is pleased to announce the official launch of it's Guide for Patients in New Zealand.…
Dr. Davids on Factors to Inform Treatment Selection in CLL
Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients…
The Role of Chemoimmunotherapy Dwindles Among New Regimens in Frontline CLL
Although frontline chemoimmunotherapy regimens have been the gold standard for patients with…
CLL Advocates NZ Newsletter Issue 4
Welcome to issue 3 of the CLL Advocates newsletter. This month's newsletter focuses on research and…
Triple Therapy for CLL Shows Promise in Phase 2 Trial
Results from a phase 2 study of 3 oral targeted agents for chronic lymphocytic leukemia (CLL)…
The CLLANZ Inaugural CLL Seminar
Three top haematologists will present and take questions on CLL disease, diagnosis and management,…
Uncommon Mutation in CLL Associated With More Favorable Prognostic Factors
Patients with CLL/small lymphocytic lymphoma (CLL/SLL) who had an MYD88 L265P mutation were…
Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia
CLL proliferate in secondary lymphatic organs where cancer cells engage in molecular and cellular…
Which Drug Therapy for CLL, Time-Limited or Continuous?
About two thirds of patients who are diagnosed with chronic lymphocytic leukemia (CLL) are…
EU approves Imbruvica plus rituximab in first-line CLL
There’s a growing recognition that some of the CAR-T shortfalls in CLL are due to an impaired…
4 October – CLL Treatments Today: What Should I Know?
Join us for a virtual town meeting for chronic lymphocytic leukemia (CLL) patients and family…
Clinical Trials Survey 2020
Please help Andrew give a powerful speech based on your experiences and thoughts around clinical…
Acalabrutinib Shows Promising Results for the Treatment of CLL
Jennifer Woyach, MD, discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib…
Online webinar: Telling Others About My CLL Diagnosis
How do you tell family and friends that you have leukemia? Chronic Lymphocytic Leukemia (CLL)…
Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL?
There’s a growing recognition that some of the CAR-T shortfalls in CLL are due to an impaired…